{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:53:17Z","timestamp":1760622797827},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.pupt.2011.01.002","type":"journal-article","created":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T12:23:10Z","timestamp":1295439790000},"page":"421-425","source":"Crossref","is-referenced-by-count":8,"title":["Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension"],"prefix":"10.1016","volume":"24","author":[{"given":"Allan J.","family":"Walkey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Fein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Horbowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harrison W.","family":"Farber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2011.01.002_bib1","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2011.01.002_bib2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A\u00a0comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pupt.2011.01.002_bib3","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2011.01.002_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2011.01.002_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.pupt.2011.01.002_bib6","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":"Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Respir CritCare Med"},{"key":"10.1016\/j.pupt.2011.01.002_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005344-200408000-00010","article-title":"Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers","volume":"44","author":"Laliberte","year":"2004","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.pupt.2011.01.002_bib8","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCULATIONAHA.107.654350","article-title":"Repeated measures","volume":"117","author":"Sullivan","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2011.01.002_bib9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1345\/aph.1E418","article-title":"Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension","volume":"39","author":"Reisbig","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pupt.2011.01.002_bib10","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4049\/jimmunol.178.3.1628","article-title":"Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities","volume":"178","author":"Aronoff","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pupt.2011.01.002_bib11","first-page":"332","article-title":"Incidence of central line infection in pulmonary hypertension patients receiving prostanoids","volume":"29","author":"Kallen","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.pupt.2011.01.002_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(95)92681-X","article-title":"Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide","volume":"346","author":"Miller","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2011.01.002_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/0091270003261343","article-title":"Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion","volume":"44","author":"Wade","year":"2004","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.pupt.2011.01.002_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ahj.2008.10.029","article-title":"Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review","volume":"157","author":"Oudiz","year":"2009","journal-title":"Am Heart J"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553911000058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553911000058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T11:25:52Z","timestamp":1544009152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553911000058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S1094553911000058"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2011.01.002","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}